169 related articles for article (PubMed ID: 22808108)
1. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.
Lange CM; Bibert S; Kutalik Z; Burgisser P; Cerny A; Dufour JF; Geier A; Gerlach TJ; Heim MH; Malinverni R; Negro F; Regenass S; Badenhoop K; Bojunga J; Sarrazin C; Zeuzem S; Müller T; Berg T; Bochud PY; Moradpour D;
PLoS One; 2012; 7(7):e40159. PubMed ID: 22808108
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.
Lange CM; Bojunga J; Ramos-Lopez E; von Wagner M; Hassler A; Vermehren J; Herrmann E; Badenhoop K; Zeuzem S; Sarrazin C
J Hepatol; 2011 May; 54(5):887-93. PubMed ID: 21145801
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
Arai T; Atsukawa M; Tsubota A; Kondo C; Shimada N; Abe H; Itokawa N; Nakagawa A; Okubo T; Aizawa Y; Iwakiri K
J Med Virol; 2015 Nov; 87(11):1904-12. PubMed ID: 25964133
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
BMC Gastroenterol; 2017 Apr; 17(1):54. PubMed ID: 28415985
[TBL] [Abstract][Full Text] [Related]
5. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.
Atsukawa M; Tsubota A; Shimada N; Abe H; Kondo C; Itokawa N; Nakagawa A; Iwakiri K; Kawamoto C; Aizawa Y; Sakamoto C
Dig Liver Dis; 2014 Aug; 46(8):738-43. PubMed ID: 24880716
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C.
Falleti E; Cmet S; Fabris C; Fattovich G; Cussigh A; Bitetto D; Ceriani E; Lenisa I; Dissegna D; Ieluzzi D; Rostello A; Pirisi M; Toniutto P
PLoS One; 2013; 8(11):e80764. PubMed ID: 24244713
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.
Petta S; Ferraro D; Cammà C; Cabibi D; Di Cristina A; Di Marco V; Di Stefano R; Grimaudo S; Mazzola A; Levrero M; Scazzone C; Craxì A
Antivir Ther; 2012; 17(5):823-31. PubMed ID: 22505587
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response.
Weintraub SJ; Fleckenstein JF; Marion TN; Madey MA; Mahmoudi TM; Schechtman KB
Am J Clin Nutr; 2012 Nov; 96(5):1025-31. PubMed ID: 23015322
[TBL] [Abstract][Full Text] [Related]
9. Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C.
El-Derany MO; Hamdy NM; Al-Ansari NL; El-Mesallamy HO
BMC Gastroenterol; 2016 Feb; 16():19. PubMed ID: 26911666
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.
Kitson MT; Sarrazin C; Toniutto P; Eslick GD; Roberts SK
J Hepatol; 2014 Dec; 61(6):1247-52. PubMed ID: 25135863
[TBL] [Abstract][Full Text] [Related]
11. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.
García-Martín E; Agúndez JA; Maestro ML; Suárez A; Vidaurreta M; Martínez C; Fernández-Pérez C; Ortega L; Ladero JM
PLoS One; 2013; 8(9):e74764. PubMed ID: 24073221
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
13. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
[TBL] [Abstract][Full Text] [Related]
14. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Younossi ZM; Birerdinc A; Estep M; Stepanova M; Afendy A; Baranova A
J Transl Med; 2012 Feb; 10():25. PubMed ID: 22313623
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
16. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
17. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.
Falleti E; Bitetto D; Fabris C; Fattovich G; Cussigh A; Cmet S; Ceriani E; Fornasiere E; Pasino M; Ieluzzi D; Pirisi M; Toniutto P
Hepatology; 2012 Nov; 56(5):1641-50. PubMed ID: 22610885
[TBL] [Abstract][Full Text] [Related]
19. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
20. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
